Press release: Q3: continued sales and earnings progress
(Paris:SAN), Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of EUR2.91 Pharma launches increased sales by 57.1%, reaching EUR1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to EUR4.2 billion, first time above EUR4 billion in a […]